Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Recruiting · NCT06982352 · Registry updated 2025-12-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, psoriasis, skin disorder | Recruiting | Phase 1 | 2025-12-19 | NCT06982352 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| LAPIX Therapeutics Inc. | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Clinical Investigations of Texas | Dallas | United States | 1 |
| Red River Research Partners | Fargo | United States | 4 |
| Triumpharma Clinical Research Unit at AlEssra Hospital | Amman | Jordan | 1 |